---
figid: PMC9406959__cells-11-02530-g005
figtitle: Current Opportunities for Targeting Dysregulated Neurodevelopmental Signaling
  Pathways in Glioblastoma
organisms:
- Lareunionomyces loeiensis
- Allium sativum
- Marchantiophyta
- Veratrum californicum
- Rhodiola crenulata
- Apopellia endiviifolia
- Anthriscus cerefolium
- Ononis spinosa
- Phlomis fruticosa
- Canis lupus familiaris
- Ovis aries
- Paraechinus aethiopicus
- Mus musculus
- Rattus norvegicus
- Drosophila melanogaster
- Caenorhabditis elegans
- Homo sapiens
- Adeno-associated virus
organisms_ner:
- Mus musculus
- Rattus norvegicus
- Ovis aries
- Canis lupus familiaris
- Drosophila melanogaster
pmcid: PMC9406959
filename: cells-11-02530-g005.jpg
figlink: /pmc/articles/PMC9406959/figure/cells-11-02530-f005/
number: F5
caption: Schematic representation of the canonical (Smad-dependent) TGFβ pathway and
  TGFβ signaling therapies which have undergone clinical trials in GBM. TGFβ binding
  to TGFβ receptors II (TGFβRII) results in phosphorylation and activation of TGFβ
  receptors I (TGFβRI), phosphorylation of Smad 2/3, which interact with Smad 4 and
  form a complex that translocates into the nucleus to activate target genes. Antisense
  oligonucleotides (AP12009), anti-integrins, kinase inhibitors (LY2157299, LY2109761)
  or neutralizing antibodies (1D11, GC1008) used for targeting TGFβ signaling pathway
  are presented in red. Based on [] and references included in the main text.
papertitle: Current Opportunities for Targeting Dysregulated Neurodevelopmental Signaling
  Pathways in Glioblastoma.
reftext: Danijela Drakulic, et al. Cells. 2022 Aug;11(16):2530.
year: '2022'
doi: 10.3390/cells11162530
journal_title: Cells
journal_nlm_ta: Cells
publisher_name: MDPI
keywords: glioblastoma | GBM subtypes | SHH signaling | Wnt/β-catenin signaling |
  Notch signaling | TGFβ signaling | BMP signaling | Hippo signaling | RA signaling
automl_pathway: 0.9515925
figid_alias: PMC9406959__F5
figtype: Figure
redirect_from: /figures/PMC9406959__F5
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9406959__cells-11-02530-g005.html
  '@type': Dataset
  description: Schematic representation of the canonical (Smad-dependent) TGFβ pathway
    and TGFβ signaling therapies which have undergone clinical trials in GBM. TGFβ
    binding to TGFβ receptors II (TGFβRII) results in phosphorylation and activation
    of TGFβ receptors I (TGFβRI), phosphorylation of Smad 2/3, which interact with
    Smad 4 and form a complex that translocates into the nucleus to activate target
    genes. Antisense oligonucleotides (AP12009), anti-integrins, kinase inhibitors
    (LY2157299, LY2109761) or neutralizing antibodies (1D11, GC1008) used for targeting
    TGFβ signaling pathway are presented in red. Based on [] and references included
    in the main text.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Tgfb1
  - Ltbp1
  - Smad4
  - Tgfbr1
  - Smad2
  - Smad3
  - Tgfbr2
  - SMAD4
  - TGFBR1
  - SMAD2
  - SMAD3
  - TGFBR2
  - dpp
  - gbb
  - put
  - mav
  - Med
  - Smox
  - Mad
---
